XML 48 R32.htm IDEA: XBRL DOCUMENT
v3.8.0.1

License and Collaboration Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract] |
License, Collaboration and Other Revenue | In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):
|  |  |  | Year Ended December 31, |
Partner |  | Agreement |  | 2017 |  |  | 2016 |  |  | 2015 |
Eli Lilly and Company |  | NKTR-358 |  | $ | 130,087 |  |  | $ | — |  |  | $ | — |
Ophthotech Corporation(1) |  | Fovista® |  |  | 19,123 |  |  |  | 1,408 |  |  |  | 1,398 |
Bayer Healthcare LLC(1) |  | BAY41-6551 (Amikacin Inhale) |  |  | 17,931 |  |  |  | 1,429 |  |  |  | 1,919 |
Baxalta Incorporated / Shire |  | ADYNOVATE® |  |  | 11,443 |  |  |  | 650 |  |  |  | 10,694 |
MAP Pharmaceuticals, Inc. / Allergan |  | SEMPRANA® |  |  | 11,000 |  |  |  | — |  |  |  | — |
Amgen, Inc. |  | Neulasta® |  |  | 5,000 |  |  |  | 5,000 |  |  |  | 5,000 |
AstraZeneca AB |  | MOVANTIK® and MOVANTIK® fixed-dose combination program |  |  | 4,600 |  |  |  | 33,000 |  |  |  | 130,000 |
Daiichi Sankyo Europe GmbH(1) |  | ONZEALDTM (NKTR-102) |  |  | 3,811 |  |  |  | 3,690 |  |  |  | — |
Roche(1) |  | PEGASYS® and MIRCERA® |  |  | — |  |  |  | 7,685 |  |  |  | 12,816 |
Other |  |  |  |  | 7,970 |  |  |  | 7,520 |  |  |  | 3,777 |
License, collaboration and other revenue |  |  |  | $ | 210,965 |  |  | $ | 60,382 |  |  | $ | 165,604 |
(1) | These collaboration agreements were completed as of December 31, 2017.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration